Our findings not only lay a solid theoretical foundation for the clinical application of TAIII but also represent a significant step forward in the ongoing efforts to address the challenge of drug resistance in EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.